DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Life Insurance Corporation Of India — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 3 hrs ago·6 Oct 2026, 11:54 am

Life Insura Corp OF India

Life Insurance Corporation of India (LICI) has received a regulatory certificate from its Registrar and Transfer Agent (RTA). This document confirms that LICI has successfully complied with the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ending September 30, 2026. The certificate is a standard compliance requirement for entities that manage dematerialized securities.

This development is a routine administrative update and does not indicate any financial distress or operational issues for the company. For investors, it simply serves as confirmation that LICI's shareholding processes are functioning as per regulatory standards. It has no immediate bearing on the stock's price or the company's core business performance.

Investors should treat this as a standard corporate disclosure with no material impact. There is no specific action required from shareholders based on this news. The focus should remain on the company's broader financial health and future business strategy.